The data demonstrated that apigenin could ameliorate neurological symptoms and reduce pathological changes and cerebral infarction volume, while increasing the number of VEGFR2/CD34 double-labeling positive EPCs which are used as a marker for proliferation of vascular endothelial cells in rats of MCAO/R. The gene discussed is KDR; the disease is cerebral infarction.